RhAPPcast

Rheumatology Advanced Practice Providers (RhAPP)
  • ٥٫٠ (٥)
  • طب

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).    Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases. 

  1. قبل ١٤ ساعة

    Medication Review: Describe The Mechanism of Action of Tirzepatide

    Explore the mechanism of action of tirzepatide in this comprehensive medication review led by Bharati Bhardwaja, PharmD, from Kaiser Permanente Colorado. This video breaks down how tirzepatide, a first-in-class dual incretin receptor agonist, targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors to improve metabolic outcomes. Learn how this once-weekly injectable therapy is FDA-approved for improving glycemic control in patients with Type 2 Diabetes and for chronic weight management in adults with obesity or overweight with comorbidities, including its role in treating obstructive sleep apnea. This educational module provides a detailed, clinically relevant overview of tirzepatide’s effects across multiple organ systems. Discover how GLP-1 receptor activation reduces appetite, slows gastric emptying, enhances insulin secretion, and decreases glucagon release, while GIP receptor agonism further supports insulin regulation, improves tolerability, and enhances fat metabolism. The combined incretin effect results in improved insulin sensitivity, reduced inflammation in adipose tissue, decreased hepatic glucose production, and meaningful weight loss outcomes. Ideal for healthcare professionals and advanced practice providers, this video offers valuable insights into the pharmacology, therapeutic benefits, and real-world applications of tirzepatide in metabolic disease management. For more expert-driven APP education, visit the RhAPP Content Rheum or access resources through the RhAPP ACE app.

    ٤ د

  2. قبل ٣ أيام

    Journal Club Review: APEX Publication

    Danielle Gatti-Palumbo, PharmD reviews the phase 3 APEX trial evaluating Guselkumab in patients with active psoriatic arthritis (PsA), highlighting its role in reducing inflammation, improving clinical outcomes, and preventing structural joint damage. The discussion emphasizes the importance of early biologic intervention in a disease that can quickly lead to irreversible damage and disability. Results show that guselkumab significantly improved ACR response rates and inhibited radiographic progression by week 24 compared to placebo, with benefits seen across multiple disease domains including joints, skin, nails, and physical function. With a favorable safety profile and durable efficacy, this IL-23 inhibitor represents a valuable treatment option for clinicians managing PsA and aiming to prevent long-term disease progression.

    ١٣ د

  3. قبل ٥ أيام

    RhAPPcast: Diagnostic Crossroads: Clues, Pitfalls, and the Journey to an HPP Diagnosis

    In this episode of RhAPPcast, host Amanda Mixon PA-C, is joined by Wendy Simmons, PA-C, they explore the diagnostic challenges of hypophosphatasia (HPP), a rare genetic metabolic bone disease that is frequently overlooked or misdiagnosed. Mixon and Simmons discuss key clinical red flags, including persistently low alkaline phosphatase, fracture patterns, dental history, and musculoskeletal pain that can mimic more common conditions such as osteoporosis or fibromyalgia. The conversation highlights the underlying biology of HPP, common diagnostic pitfalls, and the real-world burden of delayed diagnosis across the lifespan. This episode is designed to sharpen clinical reasoning, improve awareness of hypophosphatasia in rheumatology practice, and support earlier, more accurate diagnosis to improve patient outcomes.

    ٢٤ د

  4. ٢١ أبريل

    Journal Club Review: The Challenge of Hypophosphatasia Diagnosis in Adults

    In this Journal Club Review, Eileen Lydon, NP, a rheumatology provider at NYU Hospital, discusses the challenges of diagnosing hypophosphatasia (HPP) in adults, based on a 2023 Osteoporosis International publication from the HPP International Working Group. HPP is a rare genetic metabolic bone disease characterized by low alkaline phosphatase levels and highly variable, non-specific symptoms such as fractures, chronic musculoskeletal pain, and premature tooth loss—often leading to delayed or missed diagnosis. This video highlights key findings from a large literature review that identified major and minor diagnostic criteria to improve recognition of adult HPP. Clinicians will learn how to apply these criteria in practice and better differentiate HPP from conditions like osteoporosis. Designed for rheumatology providers and advanced practice providers, this overview emphasizes the importance of early identification to improve patient outcomes. For more rheumatology education, explore the Content Rheum and the RhAPP ACE app.

    ٩ د

  5. ١٦ أبريل

    FAQ: How Does Weight Reduction Impact PsA Outcomes?

    In this educational video, Shannon Ghizzoni, a physician assistant at Columbus Arthritis Center, explores the impact of weight reduction on disease activity and treatment outcomes in Psoriatic Arthritis. This discussion highlights the strong connection between obesity—particularly visceral fat—and increased inflammation in patients with psoriatic arthritis and psoriasis. Learn how excess adipose tissue contributes to a pro-inflammatory state by elevating cytokines such as Tumor Necrosis Factor alpha, Interleukin-6, and Interleukin-17—key drivers of joint inflammation, enthesitis, and skin manifestations. The video also explains how obesity may reduce the effectiveness of biologic therapies like TNF inhibitors, making weight management a critical component of comprehensive care. Additionally, this module reviews the link between psoriatic arthritis and Metabolic Syndrome, emphasizing the role of central obesity and metabolic dysfunction in worsening disease burden. A featured 2019 clinical study demonstrates that significant weight loss—achieved through a very low-calorie diet—led to meaningful improvements in disease activity, including reduced joint counts, lower CRP levels, improved psoriasis severity, and enhanced physical function. Notably, patients achieving minimal disease activity nearly doubled, with sustained benefits observed up to 24 months. This video underscores the importance of integrating weight reduction strategies alongside pharmacologic therapy to optimize outcomes in psoriatic arthritis. Discover how lifestyle interventions can create a synergistic effect with disease-modifying treatments to improve long-term patient outcomes. For more expert-driven rheumatology education, visit the RhAPP platform, explore the Content Rheum, or download the RhAPP ACE App for on-the-go learning. #PsoriaticArthritis #Rheumatology #ObesityAndInflammation #APPeducation #BiologicTherapy #TNFinhibitors #MetabolicSyndrome #ContentRheum #RhAPP

    ٤ د

  6. ١٤ أبريل

    FAQ: What Are the Neuromuscular and Functional Burdens of Living With HPP?

    In this FAQ video, Jeremy Morgan, NP, from Access Solutions Rheumatology in Tulsa, Oklahoma, discusses the neuromuscular and functional burden of hypophosphatasia (HPP), a rare and often underdiagnosed metabolic bone disease. While severe forms may present in infancy, many patients with milder HPP go unrecognized until adolescence or adulthood, experiencing chronic bone pain, joint pain, enthesitis, and recurrent foot fractures. These symptoms are frequently misdiagnosed as growing pains, fibromyalgia, or osteoporosis, leading to delayed diagnosis and inappropriate management. Patients with HPP often face significant functional limitations, including difficulty standing or walking for extended periods, reduced mobility, and challenges in daily activities, career choices, and social engagement. Dental complications, such as frequent cavities and tooth loss, further impact quality of life. This video highlights the importance of early recognition, accurate diagnosis, and appropriate management strategies for HPP, providing valuable insights for rheumatology providers and advanced practice providers. For more expert-driven rheumatology education, visit the RhAPP Content Rheum and the RhAPP ACE app.

    ٤ د

  7. ١١ أبريل

    RhAPPcast: IVIG Unpacked

    In this episode of RhAPPcast, Amanda Mixon, PA-C, and Laura Hoover, PharmD, break down the clinical use of intravenous immunoglobulin (IVIG) in rheumatology. They explore how IVIG works to modulate the immune system, where it is most effective—particularly in dermatomyositis and polymyositis—and its role as a second- or third-line option in refractory autoimmune conditions. The discussion highlights practical considerations for advanced practice providers, including weight-based dosing, infusion strategies, and the importance of premedication and hydration to reduce adverse effects. Key safety risks such as thrombosis, renal complications, and infusion reactions are reviewed, along with strategies to minimize these risks. The episode also addresses common challenges with insurance approval and patient access, offering real-world tips to navigate these barriers. With additional insights on subcutaneous options, brand differences, and monitoring considerations like IgA levels, this episode provides a concise, practical guide to safely and effectively incorporate IVIG into rheumatology care. #IVIG #Rheumatology #AutoimmuneDisease #APPs #ClinicalEducation #Immunology

    ٣٠ د

  8. ٩ أبريل

    Journal Club Review: DISCOVER-2 Severe PsA Publication

    In this journal club review module, Danielle Gatti Palumbo, PharmD, explores a post hoc analysis of a phase 3 clinical trial evaluating the efficacy of Guselkumab in biologic-naive patients with severe psoriatic arthritis (PsA). The discussion breaks down how guselkumab performs across multiple PsA disease domains, including joint involvement, skin and nail disease, enthesitis, dactylitis, and patient-reported outcomes. Psoriatic arthritis is a complex, multi-domain inflammatory condition that significantly impacts quality of life, making effective and durable treatment strategies essential for long-term disease control. The analysis highlights rapid and sustained improvements with guselkumab, with joint symptom relief seen as early as week 2 and broader disease activity improvements by week 8, maintained through 2 years. Across multiple severity cohorts, patients treated with guselkumab were significantly more likely to achieve and maintain low disease activity compared to placebo, with consistent efficacy across both every-4-week and every-8-week dosing regimens. These findings reinforce the importance of early biologic intervention and support guselkumab as a strong first-line treatment option for patients with severe PsA. Visit the RhAPP Content Rheum and the RhAPP ACE app for more rheumatology education.

    ١١ د
مشاهدة الكل (١٧٨)

التقييمات والمراجعات

٥
من ٥
‫٥ من التقييمات‬

حول

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).    Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases. 

المعلومات

  • صناع العمل
    Rheumatology Advanced Practice Providers (RhAPP)
  • سنوات النشاط
    ٢٠٢٣ - ٢٠٢٦
  • الحلقات
    ١٧٨
  • التقييم
    ملائم
  • حقوق النشر
    © 2025 RhAPPcast
  • موقع البرنامج على الويب
    RhAPPcast

قد يعجبك أيضًا